BioPharma Drug Approval
This achievement follows the recent confirmation from the Data Safety Review Committee that ISLA-101 has been deemed safe and well-tolerated in the 16 subj...
January 23, 2024 | News
AREXVY has been approved by the Therapeutic Goods Administration (TGA) for Australians 60 and over to protect against lower airway infection caused by re...
January 19, 2024 | Regulatory
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...
January 16, 2024 | News
Relivion® is a novel, non-invasive multi-channel brain neuromodulation technology. It stands out by concurrently stimulating the occipital and tri...
January 12, 2024 | News
First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...
January 09, 2024 | News
Dercum's disease is a rare disease characterized by the growth of painful lipomas. The pain can be severe, chronic (> 3 months) and often disabling. So ...
January 09, 2024 | News
This will be the second indication for which cadonilimab has received approval in China, following its use as a monotherapy treatment for recurrent or...
January 08, 2024 | News
-Bristol Myers Squibb (NYSE: BMY) announced that the European Medicines Agency (EMA) has validated its marketing authorization application for t...
January 03, 2024 | News
The approval is based on the positive results of the pivotal Phase III ReSTORE clinical trial and is supported by STRIVE's Phase II clinical trials and a...
January 01, 2024 | News
Innovative drugs often mean new treatment options for patients and advances in health care for the American public. When it comes the development of new dr...
December 29, 2023 | News
Orphan drugs, also known as drugs for rare diseases, are drugs for preventing, treating or diagnosing rare diseases. Being designated as orphan drugs will ...
December 28, 2023 | News
8MW0511, a Class 1 therapeutic biological product, is a new generation of long-acting G-CSF (modified cytokine with high activity) with independent intelle...
December 20, 2023 | News
The ALYGLO pivotal phase 3 clinical study followed FDA guidance for the treatment of patients with PI. The clinical trial (NCT02783482) GC5107B was a prosp...
December 18, 2023 | News
If Approved, HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Would Offer an up to Once-Monthly Facilitated Subcut...
December 15, 2023 | News
Most Read
Bio Jobs
News
Editor Picks